Clin2
NCT07468552Possibly a fitNot yet recruiting

Study of tirzepatide for cannabis use disorder treatment

Cannabis Use Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests whether tirzepatide (a medication that affects appetite and metabolism) can help people reduce or stop cannabis use. It is for adults who want treatment for cannabis use disorder.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have a moderate or severe cannabis use disorder (as defined by standard criteria).
  • You are interested in getting treatment for cannabis use.
  • You can understand and follow study instructions in English.
  • You are willing to take the study medication as directed and attend all visits.
  • Your body mass index (BMI) is above 23 (not underweight).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07265752Not yet recruiting· Phase 2
Tirzepatide for severe cannabis use disorder

This trial tests if tirzepatide, a hormone-like medicine, can help people with severe cannabis use disorder reduce their cannabis use. It may work by changing how your body responds to certain signals.

NCT07523633Recruiting· Phase 2
Semaglutide to help reduce cannabis use disorder

This trial tests whether a medication called semaglutide (used for weight management) can help adults with cannabis use disorder cut down or stop using cannabis. Researchers want to see if it reduces cravings and use while also monitoring overall health.

Frederiksberg
NCT05859347Recruiting
Brain stimulation study for cannabis use disorder

This trial tests whether a treatment called repetitive transcranial magnetic stimulation (a non-surgical magnetic stimulation to the brain) can help people reduce or stop cannabis use. You may be eligible if you have cannabis use disorder and meet specific safety and symptom criteria.

Toronto, Ontario
NCT07671248Not yet recruiting· Phase 3
Tirzepatide for cannabis use disorder

This study tests whether a medication called tirzepatide (originally developed for diabetes) can help people reduce or stop cannabis use. It is for adults who use cannabis frequently and are motivated to seek treatment.

Hamilton, Ontario
NCT06994338Recruiting· Phase 2
Tirzepatide for alcohol use disorder

This study tests whether a medication called tirzepatide (a once-weekly injection) can help people reduce their alcohol consumption. It is for people who drink heavily, have a high BMI, and are actively seeking help to drink less.

Los Angeles, California
NCT07559500Recruiting· Phase 1
Study of tirzepatide for alcohol use disorder

This trial tests if tirzepatide, a diabetes drug, affects brain chemistry linked to alcohol use. Researchers want to see if it can help people with mild-to-moderate alcohol use disorder who also have tried stimulants.

Bethesda, Maryland

Hear when a new Cannabis Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.